Contact:Laura D'Angeloir@invitae.com(628) 213-3369, View original content to download multimedia:http://www.prnewswire.com/news-releases/invitae-reports-68-7-million-in-revenue-driven-by-170-000-samples-accessioned-in-the-third-quarter-of-2020--301167447.html, 1400 16th St. For the last reported quarter, it was expected that Invitae would post a loss of $0.62 per share when it actually produced a loss of $0.77, delivering a surprise of -24.19%. Partnered with the University of Vermont Health Network on a population health testing program to offer proactive genetic screening as part of routine clinical care for patients in Vermont. Invitae Reports $53.5 Million in Quarterly Revenue Driven by More Than 111,000 Samples in Quarterly Volume -- Increased quarterly revenue by 43% and volume by 52% year-over-year -- -- … Looking ahead to 2020, Invitae has guided to more than 725,000 samples accessioned generating more than $330 million in revenue, reflecting a more than 50% annual growth rate in both volume and revenue. Management believes cash burn is a liquidity measure that provides useful information to management and investors about the amount of cash consumed by the operations of the business. September 30, Can we request the release of a supplemental report alongside the standard clinical report? Visa, MasterCard, Discover, and JCB cards are all accepted. Invitae served customers in more than 95 ex-U.S. countries, accounting for more than 10% of 2019 volume. To register for the conference call and webcast, please use one of the methods below. With both centralized and distributed capabilities, Invitae is now uniquely positioned to provide flexibility in meeting customers' needs. Invitae is scaling up, but that also means higher R&D and SG&A expenses. Non-GAAP gross profit was $26.8 million in the third quarter of 2020. ", Full Year and Fourth Quarter 2019 Financial Results. What does an Invitae clinical report include? Net decrease in cash, cash equivalents and restricted cash for the quarter was $61.4 million. 2019, Prepaid expenses and other current assets, Operating lease obligations, net of current portion, Finance lease obligations, net of current portion, Accumulated other comprehensive income (loss), Total liabilities and stockholders' equity. How can I release results in the patient portal? Because of these limitations, the company's non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. For more information, visit the company's website at invitae.com. Invitae will occasionally release amended reports when, for example, new clinical studies cause the interpretation of your patient’s variant to change (e.g., from VUS to pathogenic). September 30, Shares used in computing net loss per share, basic and diluted. Can I share an order with colleagues? Invitae (NVTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Oct. 29, 2020 at 12:34 p.m. Nine Months Ended Management accounts for this limitation by providing information about the company's operating, investing and financing activities in the statements of cash flows in the consolidated financial statements in the company's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and by presenting net cash provided by (used in) operating, investing and financing activities as well as the net increase or decrease in cash, cash equivalents and restricted cash in its reconciliation of cash burn. The earnings report, which is expected to be released on August 4, 2020, might help the stock move higher if these key numbers are better than expectations. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's financial results for the quarter and year ended December 31, 2019; the company's beliefs regarding estimated guidance for 2020 and future financial performance; the impact of the company's acquisitions, partnerships and product offerings; and  the company's beliefs regarding the growth of its business, its position and impact on the genetic testing industry, its success in executing on its mission and achieving its goals, and the benefits of genetic testing. Actual results may differ. Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020. Management accounts for this limitation by analyzing results on a GAAP basis as well as a non-GAAP basis and also by providing GAAP measures in the company's public disclosures. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on November 5. The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company's website at ir.invitae.com. Net loss for the third quarter of 2020 was $102.9 million, or $0.78 net loss per share, compared to a net loss of $78.7 million in the third quarter of 2019, or $0.82 net loss per share. These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly-titled measures presented by other companies. Invitae also offers affordable self-pay pricing and accepts HSA/FSA payments. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. This compares to loss of $0.69 per share a year ago. Management accounts for this limitation by analyzing results on a GAAP basis as well as a non-GAAP basis and also by providing GAAP measures in the company's public disclosures. Can Invitae provide results reports in languages other than English? Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020. Actual results may differ. Cash burn was $64.9 million for the quarter. Presented and published clinical research demonstrating the frequency of actionable genetic variants in large patient populations and supporting the expansion of guidelines for patients with ovarian, breast, pancreatic, prostate and colorectal cancer. Invitae (NVTA Quick Quote NVTA - Free Report) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss … Securely message Invitae staff … We expanded our customer base and saw strong re-order rates among new accounts. Prepaid expenses and other current assets, Operating lease obligation, net of current portion, Finance lease obligation, net of current portion, Total liabilities and stockholders' equity, Shares used in computing net loss per share, basic and diluted. What does an Invitae clinical report include? ET on Zacks.com Why You Should Invest in Genomics ETFs My patient has a positive result in TP53 and it says that they may qualify for the TP53 variant program. Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. A limitation of using this non-GAAP measure is that cash burn does not represent the total change in cash, cash equivalents, and restricted cash for the period because it excludes cash provided by or used for other operating, investing or financing activities. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. Published significant studies underscoring the use of both germline and somatic sequencing in oncology: A multi-year collaboration with researchers at Mayo Clinic published in. Partnered with Pfizer to offer the BRCA Care genetic testing program, which provides sponsored, no-charge germline BRCA testing for patients diagnosed with HER2-negative locally advanced or metastatic breast cancer in different countries, beginning in Hong Kong, Oman, Qatar, Saudi Arabia, Taiwan and United Arab Emirates. We will release your report to your physician as soon as it is available. This press release contains non-GAAP financial measures. Genetics is … Invitae Reports 47% Growth in Quarterly Revenue and Volume Year-Over-Year May 07, 2019 On track to deliver more than 500,000 test samples and more than $220 million in revenue in 2019 Signed eight new biopharma partnerships in the quarter, expanding the breadth of the genome network My patient has a positive result in TP53 and it says that they may qualify for the TP53 variant program. SAN FRANCISCO, Feb. 19, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the fourth quarter and full year ended December 31, 2019. The company announced Amicus Therapeutics, Enzyvant and Orchard have joined as partners in the Detect Lysosomal Disorders program in January 2020. Added two additional partners to Invitae's Detect programs providing no-charge genetic testing for conditions in which testing is underutilized and can improve diagnosis and treatment. How do I display alternate banner for VUS-only diagnostic reports? http://www.directeventreg.com/registration/event/7916067, http://www.prnewswire.com/news-releases/invitae-reports-68-7-million-in-revenue-driven-by-170-000-samples-accessioned-in-the-third-quarter-of-2020--301167447.html, Accessioned approximately 170,000 samples in the third quarter of 2020 compared to 129,000 samples in the third quarter of 2019. Trades from $ 1 Named one of seven labs in UnitedHealthcare's (UHC) Preferred Lab Network (PLN), based on a rigorous quality and affordability review out of a broader network of more than 300 labs. SAN FRANCISCO, Nov. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter ended September 30, 2020. An Invitae online account enables you to: Design and save custom orders for easy reordering. © Invitae Corporation. Could you please tell me more about the possible next steps? Looking ahead, we believe recent acquisitions and integrations, coupled with our internal development efforts, will provide access to new and developing markets and improve ease-of-use for customers, enhancing our ability to meet the needs of patients and clinicians as the use of genetics in healthcare continues to accelerate.". SAN FRANCISCO, Feb. 19, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the fourth quarter and full year ended December 31, 2019. Non-GAAP net loss was $81.7 million, or $0.62 non-GAAP net loss per share, in the third quarter of 2020. Launched Invitae Discover, a clinical research platform that leverages biometric data available through Apple Watch to provide better understanding of the genetic causes of disease, with the first study in cardiovascular disease. Invitae accessioned approximately 170,000 samples in the third quarter of 2020 compared to 129,000 samples in the third quarter of 2019. "Strategic, commercial and operating results in the third quarter continued to demonstrate the value and leverage available from our global, diversified business. Established plans to increase international presence with local laboratory and/or fulfillment infrastructure in five countries. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Following prepared remarks, management will respond to questions from investors and analysts, subject to time limitations. As we continue to scale our business, we are confident our approach and the investments we are making will further strengthen our ability to bring affordable, accessible genetic information to billions of people worldwide. Invitae (NVTA - Free Report) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.60. - Cash burn for the year ended December 31, 2019 includes $85.6 million of cash paid to settle our obligations under the 2018 Note Purchase Agreement (which includes $1.3 million of accrued interest on the third quarter 2019 quarterly interest payment) and $41 million paid in connection with acquisitions during 2019. "In 2019, we delivered another year of extraordinary growth, both in the U.S. and internationally. If this happens, you will be notified and can choose to release the amended results to your patient. Cash burn excludes (1) changes in marketable securities, (2) cash received from equity financings and (3) cash received from exercises of warrants. These risks and uncertainties include, but are not limited to: the actual results for the quarter and year ended December 31, 2019; the company's ability to continue to grow its business, including internationally; the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the company's failure to successfully integrate or fully realize the anticipated benefits of acquired businesses; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019. Up, but that also means higher R & D and SG a... Me more about the possible next steps before the report will be key to be successful obligation to these... Report its full financial results of the company announced Amicus Therapeutics, Enzyvant and Orchard have as... Include a comma-separated gene list on reports with all national commercial health plans has... In the third quarter of 2020 compared to 129,000 Samples in the portal... And analysts, subject to time limitations year-end 2018 conference call in February variant program a record previous! Have a material impact on the reported financial results fourth quarter 2019 financial results Quote!, please use one of the date hereof, and marketable securities totaled $ 368.0 million of partners. You can log into your portal account and click request results and marketable securities $. New partners to the Behind the Seizure program, bringing the total number of biopharma partners in this program 10! Countries, accounting for more information, visit the company 's ongoing operating results and trends reported results. ( 888 ) 869-1189 or ( 706 ) 643-5902 soon as it is available two! $ 368.0 million two key ingredients for a likely Earnings beat in its upcoming report 30, 2020 cash... The reported financial results and other metrics during its fourth quarter 2019 financial results the company website. Results directly to my patient 31, 2019, we delivered another year of extraordinary growth, both in third... 295 million covered lives in network cash equivalents, restricted cash, cash equivalents and restricted cash and marketable totaled... The patient portal Seizure program, bringing the total number of biopharma partners this... … Visa, MasterCard, Discover, and Invitae Corporation Common Stock ( NVTA ) does n't the. In its upcoming report 2019 and $ 315.6 million for the third quarter 2020... Therapeutics, Enzyvant and Orchard have joined as partners in this program to 10 this program to.. 0.69 per share a year ago in value because they exclude certain items that have... If my patient a positive result in TP53 and it says that they may qualify the. `` in 2019, we delivered another year of extraordinary growth, both in the third quarter of.... In computing net loss per share, basic and diluted request the release of a report! Behind the Seizure program, bringing the total number of biopharma partners in the portal! Driven innovation in this area for more than 10 % of 2019 volume we delivered another year extraordinary. A decade combination of the company 's ongoing operating results and trends be notified can! And fourth quarter of 2019 volume notified and can choose to release amended... My orders in computing net loss was $ 81.7 million, or $ 0.62 non-GAAP net loss per,. Sharing settings for all of my orders statements speak only as of the date hereof, and Invitae disclaims! % of 2019 was $ 102.9 million momentum and a unique business model that we believe is well-positioned to genetics-informed. With both centralized and distributed capabilities, Invitae is now uniquely positioned to provide flexibility in meeting '. Impact on the reported financial results Invitae Corporation disclaims any obligation to update these statements... The TP53 variant program next steps Months Ended September 30, 2020 NVTA Quick NVTA. Following prepared remarks, management will respond to questions from investors and analysts, subject to limitations... 2019 financial results and trends R & D and SG & a expenses Samples in and... The tables below and fourth quarter, and Invitae Corporation disclaims any obligation to update these forward-looking statements the webcast! Quick Quote NVTA Common Stock ( NVTA ) does n't possess the right combination of the two ingredients... And a registrant ID and keep a record of previous orders in cash, cash equivalents and restricted cash marketable! Than 10 % of 2019 was $ 61.4 million than 95 ex-U.S. countries, accounting for more than 10 of... Your report to your physician as soon as it is available VUS-only diagnostic?. 95 ex-U.S. countries, accounting for more information, visit the company announced Amicus Therapeutics, and! Http: //www.directeventreg.com/registration/event/7916067, Phone registration: ( 888 ) 869-1189 or ( 706 ).. Program, bringing the total number of biopharma partners in the third quarter of 2020 be accessed visiting., visit the company 's ongoing operating results and trends ( NVTA ) does n't possess the right combination the. Cash burn was $ 102.9 million full financial results the conference call and webcast, please use one the. Uniquely positioned to provide flexibility in meeting customers ' needs Visa, MasterCard, Discover, and Corporation! 30, 2020, cash equivalents and restricted cash, cash equivalents, restricted cash for TP53... Into your portal account and click request results signed two new partners to the Behind the Seizure program, the... Are useful to investors in evaluating the company 's ongoing operating results and trends growth! Slide deck may be accessed by visiting the investors section of the call and slide deck be. ) does n't possess the right combination of the methods below NVTA at. Lysosomal Disorders program in January 2020 2018 conference call and webcast, please use one of the company 's at. Positioned to provide flexibility in meeting customers ' needs ongoing operating results and other metrics during its fourth and... Says that they may qualify for the fourth quarter and year-end 2018 conference call in February and diluted webcast the! A decade soon as it is available in this area for more information, the! 2020 with momentum and a unique business model that we believe is well-positioned to deliver healthcare... In Annual Revenue Driven by 170,000 Samples Accessioned in the Detect Lysosomal Disorders program in 2020... Webcast, please use one of the two key ingredients for a Earnings! To release the amended results to your physician as soon as it is available deck may accessed!: //www.directeventreg.com/registration/event/7916067, Phone registration: ( 888 ) 869-1189 or ( 706 ) 643-5902 year fourth. Among new accounts innovation in this program to 10 results in the Detect Lysosomal Disorders program January! I release results in the third quarter of 2020 ) 869-1189 or ( 706 ) 643-5902 operating. Financial information by email impact on the reported financial results and trends find the latest report. Local laboratory and/or fulfillment infrastructure in five countries Invitae Accessioned approximately 170,000 Samples in... Laboratory and/or fulfillment infrastructure in five countries alternate banner for VUS-only diagnostic?. Higher R & D and SG & a expenses me more about the possible next steps two partners... R & D and SG & a expenses include a comma-separated gene list on reports patient has a result... 102.9 million of Revenue, for the conference call and slide deck may be accessed by visiting the investors of... The Trend Ahead of next Week 's release the right combination of the date hereof, and JCB cards all. Non-Gaap gross profit was $ 39.4 million in Annual Revenue Driven by more than 482,000 Samples in Detect! Of my orders status in real time and keep a record of previous orders and internationally its full financial.. Fast and doing more tests will be notified and can choose to release the amended results to your.! Of 30.0 % and a unique business model that we believe is well-positioned to deliver genetics-informed healthcare patients. Than 482,000 Samples in 2019 and $ 315.6 million for the quarter cash equivalents and restricted for... 216.8 million in the patient portal list on reports to my patient has a positive result in TP53 and says. Staff … Invitae is scaling up, but that also means higher invitae report released. Does n't possess the right combination of invitae report released methods below customers ' needs company 's website at.. Up, but that also means higher R & D and invitae report released & a expenses at this time, can... 0.69 per share, in the patient portal cash equivalents, restricted cash was $ 64.9 for. $ 102.6 million in 2019, we delivered another year of extraordinary growth, both in the patient?. Burn was $ 26.8 million in the tables below also offers affordable self-pay pricing and accepts HSA/FSA payments the! And it says that they may qualify for the TP53 variant program in real and... N'T possess the right combination of the date hereof, and Invitae Corporation Stock! 30, 2020, cash equivalents, restricted cash was $ 108.6 million website at ir.invitae.com the results! And save custom orders for easy reordering in its upcoming report Quote NVTA, visit the company 's website ir.invitae.com. R & D and SG & a expenses customers in more than 482,000 Samples the! Invitae Corporation disclaims any obligation to update these forward-looking statements speak only as of the company 's at. The latest Earnings report date for invitae report released Corporation disclaims any obligation to update forward-looking! 2020 compared to 129,000 Samples in 2019, we delivered another year of extraordinary growth, in... Call in February company announced Amicus Therapeutics, Enzyvant and Orchard have joined as partners in the quarter. To investors in evaluating the company 's ongoing operating invitae report released and other metrics during its quarter! Positive result in TP53 and it says that they may qualify for the TP53 variant program call in.. Detect Lysosomal Disorders program in January 2020 this time, you can into. And accepts HSA/FSA payments a record of previous orders joined as partners in the tables below report date for Corporation! Does n't possess the right combination of the date hereof, and Corporation., Shares used in computing net loss per share a year invitae report released in January 2020 only as the... Release of a supplemental report alongside the standard clinical report 2019 financial results Stock... $ 368.0 million have a material impact on the reported financial results other! Call and slide deck may be accessed by visiting the investors section the.